WO2024023766 - P13K INHIBITOR COMBINATION THERAPY
National phase entry is expected:
Publication Number
WO/2024/023766
Publication Date
01.02.2024
International Application No.
PCT/IB2023/057651
International Filing Date
27.07.2023
Title **
[English]
P13K INHIBITOR COMBINATION THERAPY
[French]
POLYTHÉRAPIE À BASE D’INHIBITEUR DE P13K
Applicants **
BERLIN-CHEMIE AG
Inventors
BINASCHI, Monica
FIASCARELLI, Alessio
LAURENT, Dirk
Priority Data
63/393,061
28.07.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3955 | |
| EPO | Filing, Examination, Granting | 55497 | |
| Japan | Filing, Examination, Granting | 3991 | |
| South Korea | Filing, Examination, Granting | 6114 | |
| USA | Filing, Examination, Granting | 18540 |
Total:
88,097
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to combinations of the P13K class I inhibitor and a selective estrogen receptor degrader (SERB) that provide synergistic effects in treating cancer. The present invention provides in particular that a combination of a P13K class la selective inhibitor such as 5-(7-methanesulfonyl-2-morpholin-4-yl- 6,7-dihydro-5H- pyrrolo[2,3-d]pyrimidin-4-yl)-pyrimidin-2-il-amine or pharmaceutically acceptable salts thereof, and the selective estrogen receptor degrader Elacestrant acts synergistically to treat breast cancer resistant to traditional treatment.[French]
La présente invention concerne des combinaisons de l’inhibiteur de P13K de classe I et d’un agent de dégradation de récepteur des oestrogènes sélectif (SERB) qui produisent des effets synergiques dans le traitement du cancer. La présente invention concerne en particulier une combinaison d’un inhibiteur sélectif de P13K de classe Ia tel que la 5-(7-méthanesulfonyl-2-morpholin-4-yl-6,7-dihydro-5H-pyrrolo[2,3-d] pyrimidin-4-yl)-pyrimidin-2-il-amine ou des sels pharmaceutiquement acceptables de celle-ci, et l’agent de dégradation de récepteur des oestrogènes sélectif élacestrant qui agit de façon synergique pour traiter un cancer du sein résistant au traitement conventionnel.